News
After US Clearance, Mabwell Secures Chinese Approval for IBD Antibody Trials
Mabwell said the NMPA has also accepted clinical trial applications for its antibody drug candidate, 9MW5211, in multiple sclerosis.
E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
Mabwell said the NMPA has also accepted clinical trial applications for its antibody drug candidate, 9MW5211, in multiple sclerosis.
HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
